Science Committee

Antibiotic Research UK’s research programmes are overseen by the Science Committee consisting of:

  • Professor Colin Garner PhD DSc FRCPath (Chief Executive)
    Professor Colin Garner
    BPharm PhD DSc FRCPath
    Chief Executive, Science Committee Member

    Colin Garner is both a university academic scientist and scientific entrepreneur. He graduated from Chelsea College, University of London (now Kings College) and did his PhD in biochemical toxicology at University College Hospital Medical School. After a two year postdoctoral fellowship at the University of Wisconsin, USA he returned to the UK to carry out cancer research at the University of Leeds and then for the majority of his career at the University of York. He headed up a cancer research laboratory in the Department of Biology for almost 20 years in which time he published over 200 scientific papers and 30 book chapters on the role of gene-environment interactions in cancer causation. Along with two surgeon colleagues, he created the York cancer charity York Against Cancer which provides funds for education, research and patient support.

    Colin founded three University of York spinout companies and is the founder of Antibiotic Research UK. He believe passionately in the new charity and says ‘there is an urgent need to develop new drugs to tackle antibiotic resistant infections as well as educating the public and professionals about antibiotic resistance. Antibiotic Research UK as a charity can make a substantial impact as it is a non-profit organisation. The Charity is working with some of the world’s experts in antibiotic resistance to reach its goal’. Colin was the founder and Director of the Jack Birch Unit for Environmental Carcinogenesis and was an Honorary Professor of Pharmacology at the Hull York Medical School, University of York.

  • Professor Chris G Dowson
    Professor Chris G Dowson
    BSc PhD
    Chairman of Science Committee

    Professor Chris G Dowson (School of Life Sciences, University of Warwick, UK) has, for many years, examined the emergence and evolution of antibiotic resistance across a wide range of bacteria. His recent focus has been to better understand how penicillin targets bacteria. This began during his postdoctoral time at the University of Sussex, in the laboratory of Professor Spratt (1986-1990) and subsequently with his Lister Institute Centenary Fellowship (1991-1996). He currently holds a personal chair at Warwick University and is a past member of the Medical Research Council Infections and Immunity Board.

    Chris’ research is highly collaborative, involving teams of biologists, chemists, engineers and physicists across universities in the UK, worldwide, and all importantly with industry, to help drive innovations from this research forward to a commercial outcome. He is involved with Antibiotic Discovery UK (AD-UK) and has been involved with research fundraising regionally across Warwickshire for the past 16 years with the Medical and Life Sciences Research Fund (MLSRF). He looks forward to brining all of this experience to help develop activities within Antibiotic Research UK (ANTRUK).

  • Dr Estée Török
    Clinician Scientist Fellow / Senior Research Associate, University of Cambridge; Honorary Consultant Microbiologist, Public Health England
    Science Committee Member

    Dr Estée Török is a Clinician Scientist Fellow and a Senior Research Associate in the Department of Medicine at the University of Cambridge. Her clinical expertise is in Infectious Diseases and Medical Microbiology, and she practices as a Consultant in Infectious Diseases and Microbiology at Cambridge University Hospitals NHS Foundation Trust.

    Dr Török has over 20 years’ clinical research experience in infectious diseases in the UK and in south-east Asia. Her current research aims to translate microbial genomics from a research tool into clinical practice, with a particular focus on antimicrobial resistance and healthcare-associated infections. She has published over 90 scientific papers and three books, and is interested in medical education and public engagement.

  • Dr Mark Sutton
    Scientific Leader – Healthcare Biotechnology at Health Protection Agency
    Science Committee Member

    Dr J. Mark Sutton obtained a PhD in Molecular Microbiology working at the John Innes Institute, Norwich in 1994. During his PhD, he developed a range of expertise in molecular genetics, molecular biology, protein chemistry, recombinant protein purification and microbiology. His PhD was followed by BBSRC-funded post-doctoral fellowships at John Innes and the University of Leeds (1994-1997), working on the generation of disease resistant transgenic plants.

    Mark joined the Centre for Applied Microbiology and Research (CAMR), Porton Down in 1997 (which became part of the Health Protection Agency in 2003 and Public Health England in 2013) and worked on a series of commercially funded studies aiming to develop new medicines derived from the properties of botulinum neurotoxin and other bacterial toxins. This developed a range of skills in molecular microbiology, protein purification, protein structure function analysis and therapeutic development. The work led to a spin out company, Syntaxin Ltd (Now acquired by Ipsen Pharmaceuticals). He spent 10 years leading a series of projects focussed on preventing the transmission of variant Creutzfeldt Jakob Disease (vCJD). These studies led to presentations to UK government advisory groups, with work cited in risks assessments and guidance documents.

    Dr Sutton became a Scientific Leader for Healthcare Biotechnology in 2009 and manages the Technology Development Group, an interdisciplinary research group within PHE’s National Infections Service. The group focusses on developing and evaluating new interventions for the treatment of healthcare associated infections (HCAIs) and antimicrobial resistance. The group developed models to assess applied infection control methods (decontamination, disinfection) and to evaluate new antimicrobial agents, working with a number of chemistry, pharmacy, physical science, electrical engineering and microbiology groups worldwide. The group established a screening and evaluation pathway for assessing the efficacy of new antimicrobials and to enable analysis of resistance that emerges during exposure to antibiotics. This uses a range of in vitro assays, in vivo infection models, with molecular genetics and embedded whole genome sequencing used to understand susceptibility and the emergence of resistance.

    Mark is a visiting Senior Lecturer at King’s College London and represents PHE on a number of advisory boards and committees, nationally and internationally. He is author on more than 60 peer-reviewed publications and a named inventor on 16 patent families, filed internationally.

  • Dr Chris Longshaw
    EU Scientific Advisor, Infectious Diseases, Shionogi Limited, UK
    Science Committee Member

    Chris is a Medical Scientific Affairs Specialist with extensive European pharmaceutical industry experience in the field of Antimicrobial Chemotherapy and Infectious Disease.

    Chris has worked in both Pharmaceutical and Crop Protection sectors, with roles spanning the full product life cycle from early phase Antimicrobial discovery and lead development, through regulatory submissions to post-market commercialization and Medical/Scientific Affairs. Currently Chris is EU Scientific Advisor, Infectious Diseases for Shionogi Pharmaceuticals and works successfully with medical, commercial and development teams at National, European and Global levels to provide medical and scientific leadership.

    Chris also has experience of coordinating microbiology research programmes ranging from large, multi-national epidemiology and resistance surveillance studies to more focused in vitro/in vivo pharmacodynamic studies supporting brand strategy and life cycle management. Chris is a graduate of the University of Leeds where he also obtained his PhD.

  • Dr David Roper
    Professor David Roper
    Professor in Microbiology, Warwick University
    Science Committee Member

    David Roper is a former MRC career Development fellow at the University of York and now reader in Structural Biology at the University Warwick. The Roper group uses structural biology techniques, principally X-ray structural determination, in combination with molecular biology and biochemical approaches, to investigate the molecular basis of microbial physiology in relation to antibiotic resistance and bacterial cell wall (peptidoglycan) biosynthesis in Gram-positive and Gram-negative pathogens.

    In addition, David’s research group also uses synthetic and translational biology approaches to obtain and reengineer pathway intermediates as chemical probes, substrates and inhibitors. This approach not only allows novel insight to the biology underpinning these pathways but also enables biotechnological exploration and exploitation.

    David was recently awarded a Personal Chair by the University of Warwick for his outstanding research contributions.

  • Professor Alasdair MacGowan
    Professor Alasdair MacGowan
    Professor of Antimicrobial Therapeutics, University of Bristol
    Science Committee Member

    Professor Alasdair MacGowan, serves as Professor of Clinical Microbiology & Antimicrobial Therapeutics at the University of Bristol, and Consultant Medical Microbiologist and Head of Research & Specialist Services in the Department of Medical Microbiology at North Bristol NHS Trust.

    Professor MacGowan has been a member of Infectious Disease Clinical Advisory Board of PolyMedix, Inc. since November 2010.

    Alisdair’s main research interests are in antibiotic resistance epidemiology in the community, and antibacterial pharmacokinetics/pharmacodynamics.

  • Professor Mark Moloney
    Professor of Organic Chemistry, University of Oxford
    Science Committee Member

    Professor Mark Moloney is currently Professor of Chemistry, having previously been Reader in Chemistry; he completed his undergraduate (B.Sc.(Hons.) and University Medal) and graduate studies (Ph.D. (Chemistry)) at the University of Sydney, Australia.

    On arriving in the UK, Mark embarked on research related to penicillin biosynthesis in the research group of Professor Sir Jack Baldwin FRS, where he worked on photoaffinity labelling studies of IPNS using an approach with diazirine-modified tripeptides to probe the enzyme binding site.

    Mark is currently working on the development of novel antibiotics through the synthesis of hybridised compounds in the hope of tackling antibacterial resistance.

  • Professor Chris Schofield
    Professor and Head of Organic Chemistry, University of Oxford
    Science Committee Member

    Professor Christopher Schofield, FRS is Professor and Head of Organic Chemistry at the University of Oxford, and has world class expertise in the chemical biology of the hypoxic response in humans and other animals with breakthrough work in the field including the identification of the hypoxia inducing factor/hydroxylases and the JmjC prolyl family of oxygenases.

    Chris has published >200 relevant papers (including in ACIE, JACS, Cell, Nature, Nat. Chem., Nat. Commun., PNAS, Science, Science Transl. Med.; >20000 citations; h-index >65). His group is highly collaborative and has been involved in multiple major research initiatives, including the EPSRC Synthesis for Biology and Medicine CDT, Oxford Center for Molecular Science, the Target Discovery Initiate, and others; he has career income for his group’s research of >£15m. Chris and his group are particularly interested in metallo-proteases and the variety of unusual enzymes involved in antibiotic biosynthesis; the carbapenems and clavam families of β-lactams are of particular interest.

  • Dr Lloyd Czaplewski
    Dr. Lloyd Czaplewski
    Chief Scientific Officer, Persica Pharmaceuticals
    Science Committee Member

    Lloyd has over 23-years of R&D experience in biological and chemical entities across multiple therapeutic areas at technical, managerial and corporate levels. For the last 15-years Lloyd has focused on antibacterial R&D, especially DNA supercoiling and bacterial cell wall biosynthesis. Career highlights include a demonstrated ability to create and lead structure-informed screening, hit & lead optimization programmes leading to compounds with class leading in vivo efficacy.

    Lloyd is a prolific inventor with a strong patent (26) and publication (34) record. He has created, managed and buillt Venture Capital funded businesses. Lloyd has a strong record of fund raising (£>23m) from UK, Europe, USA and Japan including charities (Wellcome Trust), Government (DTI, UK & NIAID, USA), Corporate (Astellas), VC investment groups and business angels. He is currently Chief Scientific Officer of Persica Pharmaceuticals.

  • Dr David Wareham
    Dr David Wareham
    Clinical Senior Lecturer / Honorary Consultant in Microbiology, Centre for Immunology and Infectious Disease, Blizard Institute, Barts and The London School of Medicine and Dentistry
    Deputy Chairman of Science Committee

    David Wareham qualified (MBBS) from the London Hospital Medical College in 1994 and trained in general medicine before specialist training in Medical Microbiology (FRCPath).

    He was awarded a Clinical Training Fellowship to study aspects of Pseudomonas aeruginosa pathogenicity at Queen Mary University in 2002 and appointed as Senior Clinical Lecturer in Microbiology in July 2005 (PhD).

    David is an Honorary Consultant Microbiologist at Barts Health NHS Trust responsible for aspects of intensive care microbiology. He heads the Antimicrobial Research Group which is involved in characterizing the mechanisms underlying the development and persistence of antimicrobial resistance as well as the consequences this may have on the organism and its capacity to cause human disease. This combines genomics, molecular biology, in-vitro and in-vivo (invertebrates) studies, epidemiological and clinical data in an attempt to dissect the complex relationship between host, pathogen and resistance. Research is driven by problems encountered in daily clinical practice and in recent years has focused on multi-drug resistant Gram-negative bacteria such as Acinetobacter baumannii, Stenotrophomonas maltophilia and carbapenem resistant Enterobacteria. Areas of particular interest include the identification of novel resistance determinants, evaluation of novel antimicrobial treatments, pharmacodynamic and pharmacokinetic analysis of new and repurposed combination therapies, virulence studies of emerging pathogens and interventions to prevent the spread of resistant organisms in the hospital environment.

  • Susan Bryan
    Susan Bryan
    Graduate of the Royal Institute of Chemistry
    Lay Member, Administrator

    Susan has worked in science and science related industries for over 40 years in various management positions including Quality Assurance, Process Improvement and Quality, Health & Safety and Environmental Management Systems. Susan spent approximately 15 years working in the animal feed industry closely involved with the management of animal medicines and over 10 years in contract research helping to develop new drugs.

    Susan wanted to become involved with ANTRUK due to the exciting work they are undertaking to help combat antimicrobial and antibiotic drug resistance and hopes that her skills and experience will help support this important work.